



MedinCell's partner Teva provides Guidance for UZEDY in 2024 and an Update on the treatment-candidate of Olanzapine Long-Acting Injectable (LAI)

Euronext : MEDCL - Montpellier - France - 31 January 2024 - 9:30pm (CET)

-
- Guidance for 2024 UZEDY Teva's revenue: ~ \$80 million
 - Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed
-

About UZEDY

During the Q4 2023 earnings call held today by Teva Pharmaceutical Industries Ltd., President and CEO Richard Francis stated that he expects a strong uptake and significant growth for UZEDY in 2024. He notably provided the annual revenue guidance for UZEDY, projecting approximately \$80 million for 2024.

This revenue projection is aligned with MedinCell's forecasted earnings from UZEDY, as the company receives royalties on sales and may earn up to \$105 million in commercial milestones.

UZEDY is the first product based on MedinCell's long-acting injection technology, BEPO, to reach commercial stage

- US marketing authorization obtained from the U.S. FDA on April 28, 2023
- Commercial launch by Teva in May 2023
- MedinCell has already received first royalties of €0.6 million, calculated on Teva's net sales from mid-May to end of September 2023

About Olanzapine LAI (mdc-TJK)

Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, announced during the call that 62% of the targeted 3,600 injections have already been performed as part of the ongoing Phase 3 clinical trial and that no PDSS has been observed. Full clinical package on efficiency and safety is expected in the second half of 2024.

mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. It has the potential to be the first long-acting Olanzapine with a favorable safety profile as other LAIs of Olanzapine have a FDA black box warning for PDSS that limits their use.

Teva is fully responsible to lead the development and commercialization of olanzapine LAI globally.

MedinCell may receive up to \$117 million in development and commercial milestones over the coming years for mdc-TJK, and is eligible for royalties on all net sales.

Christophe Douat, CEO of MedinCell, says: *"The guidance on UZEDY is very positive. Teva's ambition reaffirms its confidence in its potential. Olanzapine LAI Phase 3, potential First-in-Class product, is progressing impressively and is ahead of schedule with a major milestone this year. Both illustrate the ability of MedinCell technology to do breakthrough products. Based on these news, we confirm our objective to achieve operational profitability as soon as possible and to generate additional revenue with new partnerships to extend our cash visibility until this horizon."*

About MedinCell

MedinCell is a clinical- and commercial-stage biopharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on

BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO technology is licensed to Teva under the name SteadyTeq™).

We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals

www.medincell.com

Contacts

David Heuzé - Head of Communications

david.heuze@medincell.com / +33 (0)6 83 25 21 86

Media Relations

Nicolas Mérigeau

medincell@newcap.eu / +33 (0)1 44 71 94 94

Investor Relations France

Louis-Victor Delouvrier/Alban Dufumier

medincell@newcap.eu / +33 (0)1 44 71 94 94

Head of US Financial Strategy & IR

Grace Kim

grace.kim@medincell.com / +1 (646) 991-4023

This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are encouraged to inquire about, and required to comply with, these restrictions.